newsfilter
← Latest News
PR Newswire·

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Phase 2 Bryostatin-1 Severe Cohort secondary and exploratory endpoint data selected by independent committee for presentation NEW YORK, July 13, 2023 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX)